Works by Kirschbrown, Whitney

Results: 11

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.

Published in:

Journal of Clinical Pharmacology, 2021, v. 61, n. 8, p. 1096, doi. 10.1002/jcph.1855

By:

Liu, Stephanie N.;
Lu, Tong;
Jin, Jin Y.;
Li, Chunze;
Girish, Sandhya;
Melnikov, Fjodor;
Badovinac Crnjevic, Tanja;
Machackova, Zuzana;
Restuccia, Eleonora;
Kirschbrown, Whitney P.

Publication type:

Article

Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study.

Published in:

Journal of Clinical Pharmacology, 2019, v. 59, n. 5, p. 702, doi. 10.1002/jcph.1362

By:

Kirschbrown, Whitney P.;
Kågedal, Matts;
Wang, Bei;
Nijem, Ihsan;
Eng‐Wong, Jennifer;
Garg, Amit;
Wynne, Chris;
Wada, Russ;
Li, Hanbin;
Badovinac Crnjevic, Tanja;
Gasser, Helena;
Heeson, Sarah

Publication type:

Article

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.

Published in:

2019

By:

Agarwal, Suresh;
Gopalakrishnan, Sathej;
Mensing, Sven;
Potluri, Jalaja;
Hayslip, John;
Kirschbrown, Whitney;
Friedel, Anna;
Menon, Rajeev;
Salem, Ahmed Hamed

Publication type:

journal article

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Published in:

2022

By:

Wang, Bei;
Deng, Rong;
Hennig, Stefanie;
Badovinac Crnjevic, Tanja;
Kaewphluk, Monika;
Kågedal, Matts;
Quartino, Angelica L.;
Girish, Sandhya;
Li, Chunze;
Kirschbrown, Whitney P.

Publication type:

Correction Notice

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 3, p. 499, doi. 10.1007/s00280-021-04296-0

By:

Wang, Bei;
Deng, Rong;
Hennig, Stefanie;
Badovinac Crnjevic, Tanja;
Kaewphluk, Monika;
Kågedal, Matts;
Quartino, Angelica L.;
Girish, Sandhya;
Li, Chunze;
Kirschbrown, Whitney P.

Publication type:

Article

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Published in:

2019

By:

Kirschbrown, Whitney P.;
Wang, Bei;
Nijem, Ihsan;
Ohtsu, Atsushi;
Hoff, Paulo M.;
Shah, Manish A.;
Shen, Lin;
Kang, Yoon-Koo;
Alsina, Maria;
Girish, Sandhya;
Garg, Amit

Publication type:

journal article

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

Published in:

2019

By:

Kirschbrown, Whitney P.;
Kågedal, Matts;
Wang, Bei;
Lindbom, Lars;
Knott, Adam;
Mack, Rachelle;
Monemi, Sharareh;
Nijem, Ihsan;
Girish, Sandhya;
Freeman, Christie;
Fumagalli, Debora;
McConnell, Robin;
Jerusalem, Guy;
Twelves, Chris;
Baselga, José;
von Minckwitz, Gunter;
Bines, José;
Garg, Amit

Publication type:

journal article

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin<sup>®</sup>), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors.

Published in:

2019

By:

Quartino, Angelica L.;
Li, Hanbin;
Kirschbrown, Whitney P.;
Mangat, Ranvir;
Wada, D. Russell;
Garg, Amit;
Jin, Jin Y.;
Lum, Bert

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Kirschbrown, Whitney;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].

Published in:

International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276

By:

Wu, Huali;
Infante, Jeffrey R;
Keedy, Vicki L;
Jones, Suzanne F;
Chan, Emily;
Bendell, Johanna C;
Lee, Wooin;
Kirschbrown, Whitney P;
Zamboni, Beth A;
Ikeda, Satoshi;
Kodaira, Hiroshi;
Rothenberg, Mace L;
III, Howard A Burris;
Zamboni, William C

Publication type:

Article

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Published in:

International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911

By:

Huali Wu;
Infante, Jeffrey R.;
Keedy, Vicki L.;
Jones, Suzanne F.;
chan, Emily;
Bendell, Johanna C.;
lee, Wooin;
Kirschbrown, Whitney P.;
Zamboni, Beth A.;
Ikeda, Satoshi;
Kodaira, Hiroshi;
Rothenberg, Mace L.;
Burris III, Howard A.;
Zamboni, William C.

Publication type:

Article